Harold Pretorius, MD
Nuclear Medicine · Bellevue, KYNPI 1760431159
Payments from drug & device makers
Across 2,147 payments — averaging $74.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$36K
- Amarin Pharma, Inc.$29K
- Mannkind Corporation$20K
- Corcept Therapeutics$17K
- Clarus Therapeutics Inc.$15K
- AbbVie$14K
- plus $28K from 54 others
What the payments were for
- Consulting fees$21,40013%
- Speaking & faculty fees$94,42059%
- Travel & lodging$6,6654%
- Food & beverage$35,87823%
- Education$4770%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JATENZO$41,947
- FARXIGA$34,532
- Vascepa$27,163
- AFREZZA$18,016
- Synthroid$9,200
- Tirosint$4,225
- iLet Bionic Pancreas$888
- Korlym$495
- BRILINTA$482
- KISUNLA$363
- JARDIANCE$343
- Repatha$242
- PRALUENT$236
- VRAYLAR$236
- LOKELMA$182
- SYMBICORT$177
- BEVESPI AEROSPHERE$177
- SYNERGY ABLATION SYSTEM$139
- CRENESSITY$137
- LINZESS$129
How this compares
Too few nuclear medicine providers in Kentuckyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 176 | $231,467 |
| TrulicityDulaglutide | 115 | $153,950 |
| FarxigaDapagliflozin Propanediol | 187 | $142,050 |
| GenotropinSomatropin | 19 | $123,401 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $112,674 |
| OzempicSemaglutide | 98 | $111,117 |
| KorlymMifepristone | 13 | $104,884 |
| AfrezzaInsulin Regular, Human | 49 | $99,745 |
| VascepaIcosapent Ethyl | 160 | $97,864 |
| EliquisApixaban | 85 | $94,310 |
| Bydureon BciseExenatide Microspheres | 40 | $56,169 |
| Xigduo XrDapaglifloz Propaned/Metformin | 55 | $46,366 |
| JardianceEmpagliflozin | 46 | $41,364 |
| KerendiaFinerenone | 41 | $38,039 |
| TrintellixVortioxetine Hydrobromide | 48 | $30,793 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,947 | $385,418291 claims |
| PfizerGenotropin, Eliquis | $1,081 | $217,710104 claims |
| AstraZenecaFarxiga | $35,851 | $142,050187 claims |
| Novo NordiskOzempic, Novolog | $1,818 | $117,571140 claims |
| Corcept TherapeuticsKorlym | $16,824 | $104,88413 claims |
| Mannkind CorporationAfrezza | $20,352 | $99,74549 claims |
| Boehringer IngelheimJardiance | $864 | $41,36446 claims |
| BayerKerendia | $933 | $38,03941 claims |
| AbbVieVraylar, Synthroid | $13,527 | $34,706109 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $160 | $30,79348 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCCycloset | $570 | $16,80111 claims |
| NovartisEntresto | $406 | $13,01119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nuclear medicine providers in Kentuckyon file to place this against a meaningful peer group, so we don't.
Other nuclear medicine in Bellevue
- Yiyan LiuLouisville$92
- Ajit ShahLexington$19
- Naghmehossadat EshghiLexington$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.